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To identify the risk factors for developing subsequent bladder carcinoma in patients undergoing surgical
management of urothelial carcinoma (UC) of the upper urinary tract, we retrospectively studied 119 (median
age 69, 81 males and 38 females) patients who underwent surgical resection at Yokohama Municipal Citizen’s
Hospital, Yokosuka Kyousai Hospital and Chigasaki Municipal Hospital from August 1980 to September
2006. After a median follow up of 37.7 months, 42 cases (35.3%) developed recurrent bladder cancer and
the intravesical recurrence-free survival rate at 5 years (Kaplan-Meier method) was 57.7%. Bladder cancer
was significantly more common in patients who had smaller primary tumors (less than 3 cm : p＝0.0444) by
univariate analysis. This factor was also identified as independent predictor for the intravesical recurrence
by multivariated analysis (p＝0.0495, Hazard ratio 2.099). In 42 intravesical recurrence cases, invasive
recurrence was seen in 9 cases (21.4%). Invasive recurrence appeared to occur in the patients who were
older and had longer interval by intravesical recurrence.
(Hinyokika Kiyo 56 : 355-359, 2010)




















status を考慮しつつ，多くは MVAC または MEC 療









多変量解析は Cox-proportional hazard model を用いて







進達度との関連を χ 二乗検定・Mann-Whitney U test






た．119症例の臨床所見の内訳を Table 1 に，病理所







はこれらの一区分内のみに存在し (single focus 114
例），尿管と腎盂の多発症例は (multifocal) 5 例で
あった．大きさでは 3 cm 未満の症例が多くを占めて
いた（75例）．病理所見では，pT2 以上の浸潤癌は62
例と約半数をしめ，64例（53.8％）が grade 3 症例で
あった．術式であるが，119例中105例で開腹による腎
尿管全摘術が施行された．鏡視下腎尿管全摘は 7例，






Table 1. Patient characteristics (clinical status)
年 齢 中央値 69
平 均 67.6±10.5（32-86)
性 別 男性/女性 81/38
左 右 左/右 55/64
施 設 横浜市民病院 34
横須賀共済病院 62
茅ヶ崎市立病院 23





最大腫瘍径 3 cm 未満 75
3 cm 以上 44




補助化学療法 施 行 26
施行せず 93





















Fig. 1. Clinical courses of 119 cases for survival.
泌56,07,02-2
Fig. 2. Intravesical recurrence-free rate of all
patients (n＝119) : 5 year-intravesical recur-
rence free rate was 57.7％.









































Table 3. Univariate and multivariate analyses of association between various parameters and development of bladder





Favorable Unfavorable Hazard ratio p value
1 Age ＜69 ≧69 0.3202 NA
2 Sex Female Male 0.1202 NA
3 Focus Single Multiple 0.1091 NA
4 Size ≧3 cm ＜3 cm 0.0444 2.099 0.0495
5 pT Tis, Ta, T1 T2, T3, T4 0.0976 NA
6 Grade 1, 2 3 0.5261 NA
7 op Total Partial 0.9422 NA
8 Chemotherapy None Done 0.4612 NA
9 v (n＝93) Negative Positive 0.5788 NA
10 ly (n＝91) Negative Positive 0.1007 NA
11 inf (n＝41) α β, γ 0.4474 NA
Table 4. Frequency of clinical and pathologic





Age (Years) 66.5±11.9 75.7±5.8 0.012*
Sex Male 28 5 0.0576
Female 5 4
Focus Single 30 9 0.3479
Multiple 3 0
Size ＜3 cm 25 8 0.3948
≧3 cm 8 1
pT Tis, Ta, T1 16 2 0.1582
T2, T3, T4 17 7
Grade 1, 2 16 3 0.6107
3 17 6
op Total 31 9 0.4492
Partial 2 0
Chemotherapy None 26 8 0.4939
Done 7 1
v (n＝34) Negative 21 4 0.4343
Positive 7 2
ly (n＝36) Negative 19 3 0.4226
Positive 10 4
inf (n＝17) α 7 0 0.1362
β, γ 6 4
Interval by ini-
tial recurrence (Months) 18.9±46.9 24.7±21.9 0.0358
*
* Mann-Whitney U test.


































































また Shikanov らは high grade の上部尿路上皮癌での
膀胱再発は半数が high grade であり，一方 low grade
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